Research programme: hepatitis B antivirals - PharmassetAlternative Names: Hepatitis B antivirals - Pharmasset; L-3'-FD4C; β-L-3'-Fluoro-2',3'-didehydro-2,3'-dideoxycytidine
Latest Information Update: 29 Aug 2007
At a glance
- Originator Emory University; Pharmasset
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 29 Sep 2003 Preclinical trials in Hepatitis B treatment in USA (unspecified route)